http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/7BAA6E5A_D907_46ED_9448_89C66A3B88EC_175243.pdf
Q2 results are out
Flat topline
Good growth in NP 44cr vs 34 cr EPS 48.4 vs 37.6
Posts in category Value Pickr
Avanti Feeds (07-11-2015)
Capital First – 72% Held by Warburg Pincus (07-11-2015)
Sub 10% RoE for the past 3 years, and also in H1 FY 16. Higher provisioning norms has diluted the effect of higher operating leverage. Operating Income / Average Assets however has risen significantly - would this be due to higher growth of consumer durable financing?
Indian Toners and Developers: Value buy or value trap? (07-11-2015)
the FCF is not 17 Cr but 17.61cr - 11.27cr (Capex) = 6.34 cr ( March 2015 AR). But yes its undervalued - its earning a FCF yield of 20%+ on the EV of 30cr (74 cap - 45 cr investments & cash)
Alembic & Alembic Pharma (07-11-2015)
Hi Rohit,
You can search about patent expiry for ANDAs on Orange book (for biologicals you have purple book which is available in pdf) which is their USFDA website. There you can type the molecule name and get data about the patent expiry.
I dont have much clarity about when the generic can be launched on exclusivity expiry or patent expiry. Actually, it varies from molecule to molecule. A drug can have various patent and exclusivity expiry dates. Even in exclusivity, there are various classifications like New Chemical Entity, Paediatric drug, Orphan Drug etc and an extension is given in case of any of these classifications (extension beyond the regular 5 years of exclusivity). Also, there can be some agreement which a generic player can enter with innovator eg Alembic has USFDA approval for gPristiq but hasnt launched it yet as per agreement with innovator because of various issues like litigations etc. I usually google about generic entry of a specific molecule. But still too difficult to predict.
Alembic & Alembic Pharma (07-11-2015)
Hi Sta,
I havent looked at Auro, so cant comment.
Alembic & Alembic Pharma (07-11-2015)
Hi @ankitgupta
I am trying to understand exclusivity better. I tried to search a bit on USFDA site but didnt understand anything. You said above that the Exclusivity expires on Dec28, 2017 and Patent expires in in Dec 2019. So what happens in the period in between?
Is it so that no one can even file and ANDA for a drug that is under exclusivity?
Ambika Cotton Mills (07-11-2015)
Average results from Ambika.
No growth in revenue and profit
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/4B21AD1E_20F1_4885_925F_58EFCA2AA1AF_154105.pdf
Indian terrain—play on consumption (07-11-2015)
Very good numbers from Indian Terrain
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/23A20535_5212_4705_934A_81D7915074D9_154029.pdf
One must note that last year festival season sales came in Q2. But this year festival season is in Q3. In that aspect result is very good.
Alembic & Alembic Pharma (07-11-2015)
@ankitgupta- how do u see aurobindo pharma inthis context. from what i get is they have the highest number of filing with USFDA. would love your views
Need for KYC to be enforced when Forum Abuse is detected (07-11-2015)
Everything depends on one single decision - is admin/moderator/valuepickr in its totality responsible for content ? If you say yes then you will have to vet new threads,read thro' each posts,confirm for balanced views etc etc . Its not practical in the long run.If you say no then this can be another Money control where over medium term brand will surely get diluted.What i suggested as a one time rank is a via media absolving too much effort by admin trying to counter motivated posters but at the same time having a control over the thread because the "rank " that they give will override a 1000 words and anyone who reads the thread will ask " why valuepickr seniors are giving this stock a ranking of 5 and calling it a suspect idea " ?